US Patent 7223744 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
Patent 7223744 was granted and assigned to Inspire Pharmaceuticals on May, 2007 by the United States Patent and Trademark Office.
All edits
The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds, or hydrolysis-resistant mononucleoside triphosphate salts. The present invention also provides P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.
US Patent 07223744 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof US Patent 7223744 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US Patent 07223744 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
Find more entities like US Patent 7223744 Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
